Transdermal Rotigotine: A Clinically Innovative Dopamine‐Receptor Agonist for the Management of Parkinson's Disease
Identifieur interne : 000926 ( Main/Exploration ); précédent : 000925; suivant : 000927Transdermal Rotigotine: A Clinically Innovative Dopamine‐Receptor Agonist for the Management of Parkinson's Disease
Auteurs : Chen [États-Unis] ; Swope [États-Unis] ; Dashtipour [États-Unis] ; Lyons [États-Unis]Source :
- Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy [ 0277-0008 ] ; 2009-12.
English descriptors
- KwdEn :
Abstract
Rotigotine is a highly lipophilic dopamine‐receptor agonist and the first transdermally delivered agent to demonstrate efficacy and safety as monotherapy in early Parkinson's disease and to reduce “off” hours in levodopa‐treated patients with advanced Parkinson's disease. The rotigotine pharmacophore is nonergolinic and demonstrates high affinity for dopamine D2 and D3 receptors. With once‐daily application, the patch matrix provides continuous, nonfluctuating plasma drug levels at steady state, resulting in continuous and steady plasma and brain levels and striatal dopamine‐receptor stimulation. In early Parkinson's disease, doses of rotigotine up to 8 mg/24 hours demonstrate comparable efficacy to ropinirole (at doses up to 12 mg/day); in advanced Parkinson's disease, doses of rotigotine up to 16 mg/24 hours demonstrate comparable efficacy and tolerability to pramipexole (at doses up to 4.5 mg/day). In the registration trials for early and advanced Parkinson's disease, the adverse effects most commonly observed with rotigotine were minor application site reactions, dizziness, nausea, and somnolence. Doses of transdermal rotigotine can be titrated to a maintenance dose within 2–3 weeks, and the once‐daily regimen minimizes complexity of therapy. The transdermal delivery system is also an advantage when nonoral administration is desired, and the 24‐hour, continuous, nonfluctuating drug levels can improve early morning and nocturnal symptoms of Parkinson's disease. Thus, transdermally delivered rotigotine is a clinically innovative and useful addition to the dopamine‐receptor agonist class. This review summarizes the key pharmacologic and clinical data for rotigotine and provides a focused clinical context for its use in early‐to‐advanced Parkinson's disease, as well as a brief summary for its role in restless legs syndrome.
Url:
DOI: 10.1592/phco.29.12.1452
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Transdermal Rotigotine: A Clinically Innovative Dopamine‐Receptor Agonist for the Management of Parkinson's Disease</title><author><name sortKey="Chen" sort="Chen" uniqKey="Chen" last="Chen">Chen</name></author><author><name sortKey="Swope" sort="Swope" uniqKey="Swope" last="Swope">Swope</name></author><author><name sortKey="Dashtipour" sort="Dashtipour" uniqKey="Dashtipour" last="Dashtipour">Dashtipour</name></author><author><name sortKey="Lyons" sort="Lyons" uniqKey="Lyons" last="Lyons">Lyons</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:BB2DC33537842199BCD031BACB92FD2ADBFA67F8</idno><date when="2009" year="2009">2009</date><idno type="doi">10.1592/phco.29.12.1452</idno><idno type="url">https://api.istex.fr/document/BB2DC33537842199BCD031BACB92FD2ADBFA67F8/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000261</idno><idno type="wicri:Area/Main/Curation">000215</idno><idno type="wicri:Area/Main/Exploration">000926</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Transdermal Rotigotine: A Clinically Innovative Dopamine‐Receptor Agonist for the Management of Parkinson's Disease</title><author><name sortKey="Chen" sort="Chen" uniqKey="Chen" last="Chen">Chen</name><affiliation wicri:level="2"><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Department of Pharmacotherapy and Outcomes Science, School of Pharmacy, Loma Linda University, Loma Linda</wicri:cityArea></affiliation><affiliation wicri:level="2"><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Movement Disorders Center, Department of Neurology, School of Medicine, Loma Linda University, Loma Linda</wicri:cityArea></affiliation></author><author><name sortKey="Swope" sort="Swope" uniqKey="Swope" last="Swope">Swope</name><affiliation wicri:level="2"><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Movement Disorders Center, Department of Neurology, School of Medicine, Loma Linda University, Loma Linda</wicri:cityArea></affiliation></author><author><name sortKey="Dashtipour" sort="Dashtipour" uniqKey="Dashtipour" last="Dashtipour">Dashtipour</name><affiliation wicri:level="2"><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Movement Disorders Center, Department of Neurology, School of Medicine, Loma Linda University, Loma Linda</wicri:cityArea></affiliation></author><author><name sortKey="Lyons" sort="Lyons" uniqKey="Lyons" last="Lyons">Lyons</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Kansas</region></placeName><wicri:cityArea>Department of Neurology, University of Kansas Medical Center, Kansas City</wicri:cityArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy</title><idno type="ISSN">0277-0008</idno><idno type="eISSN">1875-9114</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2009-12">2009-12</date><biblScope unit="volume">29</biblScope><biblScope unit="issue">12</biblScope><biblScope unit="page" from="1452">1452</biblScope><biblScope unit="page" to="1467">1467</biblScope></imprint><idno type="ISSN">0277-0008</idno></series><idno type="istex">BB2DC33537842199BCD031BACB92FD2ADBFA67F8</idno><idno type="DOI">10.1592/phco.29.12.1452</idno><idno type="ArticleID">PHAR544</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0277-0008</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>DRA</term><term>Parkinson's disease</term><term>RLS</term><term>dopamine‐receptor agonist</term><term>restless legs syndrome</term><term>rotigotine</term><term>transdermal administration</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Rotigotine is a highly lipophilic dopamine‐receptor agonist and the first transdermally delivered agent to demonstrate efficacy and safety as monotherapy in early Parkinson's disease and to reduce “off” hours in levodopa‐treated patients with advanced Parkinson's disease. The rotigotine pharmacophore is nonergolinic and demonstrates high affinity for dopamine D2 and D3 receptors. With once‐daily application, the patch matrix provides continuous, nonfluctuating plasma drug levels at steady state, resulting in continuous and steady plasma and brain levels and striatal dopamine‐receptor stimulation. In early Parkinson's disease, doses of rotigotine up to 8 mg/24 hours demonstrate comparable efficacy to ropinirole (at doses up to 12 mg/day); in advanced Parkinson's disease, doses of rotigotine up to 16 mg/24 hours demonstrate comparable efficacy and tolerability to pramipexole (at doses up to 4.5 mg/day). In the registration trials for early and advanced Parkinson's disease, the adverse effects most commonly observed with rotigotine were minor application site reactions, dizziness, nausea, and somnolence. Doses of transdermal rotigotine can be titrated to a maintenance dose within 2–3 weeks, and the once‐daily regimen minimizes complexity of therapy. The transdermal delivery system is also an advantage when nonoral administration is desired, and the 24‐hour, continuous, nonfluctuating drug levels can improve early morning and nocturnal symptoms of Parkinson's disease. Thus, transdermally delivered rotigotine is a clinically innovative and useful addition to the dopamine‐receptor agonist class. This review summarizes the key pharmacologic and clinical data for rotigotine and provides a focused clinical context for its use in early‐to‐advanced Parkinson's disease, as well as a brief summary for its role in restless legs syndrome.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Californie</li><li>Kansas</li></region></list><tree><country name="États-Unis"><region name="Californie"><name sortKey="Chen" sort="Chen" uniqKey="Chen" last="Chen">Chen</name></region><name sortKey="Chen" sort="Chen" uniqKey="Chen" last="Chen">Chen</name><name sortKey="Dashtipour" sort="Dashtipour" uniqKey="Dashtipour" last="Dashtipour">Dashtipour</name><name sortKey="Lyons" sort="Lyons" uniqKey="Lyons" last="Lyons">Lyons</name><name sortKey="Swope" sort="Swope" uniqKey="Swope" last="Swope">Swope</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000926 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000926 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:BB2DC33537842199BCD031BACB92FD2ADBFA67F8
|texte= Transdermal Rotigotine: A Clinically Innovative Dopamine‐Receptor Agonist for the Management of Parkinson's Disease
}}
| This area was generated with Dilib version V0.6.23. |  |